Literature DB >> 2452031

Degradation of melphalan in vitro: rationale for the use of continuous exposure in chemosensitivity assays.

A G Bosanquet1, M C Bird.   

Abstract

The hydrolysis of melphalan in cell culture medium at 37 degrees C has been studied. Degradation of melphalan proceeded via monohydroxy-melphalan (MOH) to dihydroxymelphalan [M(OH)2] with a half-life of 66 min for melphalan and 58 min for MOH. The half-life for melphalan was similar to the terminal half-life of the drug in vivo. The effect of the two metabolites, MOH and M(OH)2, on the chemosensitivity of K562 leukaemia cells during continuous exposure to melphalan was also examined. M(OH)2 had no potentiating effect on melphalan cytotoxicity at concentrations up to 100 micrograms/ml. MOH also had little effect on cell kill at concentrations higher than those commonly achieved during in vitro chemosensitivity assays. The LD50 for 1 h exposure to melphalan was twice that for continuous exposure: this also suggests no interference by MOH and M(OH)2. These data suggest that continuous exposure of melphalan in in vitro chemosensitivity assays is probably preferable to the arbitrary 1 h drug exposure time commonly employed.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2452031     DOI: 10.1007/bf00262772

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  17 in total

1.  Stability of melphalan solutions during preparation and storage.

Authors:  A G Bosanquet
Journal:  J Pharm Sci       Date:  1985-03       Impact factor: 3.534

2.  The pharmacokinetics of melphalan in patients with multiple myeloma: an intravenous/oral study using a conventional dose regimen.

Authors:  K W Woodhouse; P Hamilton; A Lennard; M D Rawlins
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

3.  Pharmacologic studies of anticancer drugs with the human tumor stem cell assay.

Authors:  D S Alberts; S E Salmon; H S Chen; T E Moon; L Young; E A Surwit
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

4.  A comparative assessment of the in vitro effects of drugs on cells by means of colony assays or flow microfluorimetry.

Authors:  B T Hill; R D Whelan; H T Rupniak; L Y Dennis; M A Rosholt
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

5.  Measurement of plasma melphalan at therapeutic concentrations using isocratic high-performance liquid chromatography.

Authors:  A G Bosanquet; E D Gilby
Journal:  J Chromatogr       Date:  1982-11-12

6.  Comparison of the fed and fasting states on the absorption of melphalan in multiple myeloma.

Authors:  A G Bosanquet; E D Gilby
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

7.  Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma.

Authors:  A G Bosanquet; E D Gilby
Journal:  Eur J Cancer Clin Oncol       Date:  1982-04

8.  Concentration and time-dependent inter-relationships for antitumour drug cytotoxicities against tumour cells in vitro.

Authors:  H T Rupniak; R D Whelan; B T Hill
Journal:  Int J Cancer       Date:  1983-07-15       Impact factor: 7.396

9.  A novel dye exclusion method for testing in vitro chemosensitivity of human tumors.

Authors:  L M Weisenthal; J A Marsden; P L Dill; C K Macaluso
Journal:  Cancer Res       Date:  1983-02       Impact factor: 12.701

10.  Quantitation of chemosensitivity in acute myelocytic leukaemia.

Authors:  M G Lihou; P J Smith
Journal:  Br J Cancer       Date:  1983-10       Impact factor: 7.640

View more
  2 in total

1.  Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines.

Authors:  Benigno C Valdez; Yago Nieto; David Murray; Yang Li; Guiyun Wang; Richard E Champlin; Borje S Andersson
Journal:  Exp Hematol       Date:  2012-06-09       Impact factor: 3.084

2.  An inverse switch in DNA base excision and strand break repair contributes to melphalan resistance in multiple myeloma cells.

Authors:  Mirta M L Sousa; Kamila Anna Zub; Per Arne Aas; Audun Hanssen-Bauer; Aida Demirovic; Antonio Sarno; Erming Tian; Nina B Liabakk; Geir Slupphaug
Journal:  PLoS One       Date:  2013-02-06       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.